ClinicalTrials.gg
Not yet recruitingNCT07205913MINDUpdated Mar 9, 2026

Gut Microbiota, Diet-INDuced Obesity and Type 2 Diabetes in New Caledonia - MIND

An observational study in Diabetes Mellitus, Type 2 and Obesity, sponsored by Institut Pasteur. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Institut Pasteur · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
270
Ages
18 Years and older
Sex
All
01

Study summary

In recent years, the global rise in obesity and type 2 diabetes has become a major public health issue. In New Caledonia, 38% of the adult population has a body mass index ≥30. At the same time, the prevalence of type 2 diabetes continues to rise steadily. The burden of these diseases does not affect communities uniformly. While known factors such as diet, physical activity, and socioeconomic conditions play a role, studies have demonstrated the involvement of the gut microbiota in the development of metabolic disorders, particularly obesity and insulin resistance. However, this area remains largely unexplored in New Caledonia and the Pacific.

Read the detailed description

The goal of the study is to describe and characterize the gut microbiota and fecal metabolome of participants and study the relationships between microbiota composition and bioclinical parameters in participants with different metabolic states, ranging from "metabolically healthy" to severe obesity with and without type 2 diabetes.

To achieve this goal, adults in New Caledonia divided in 3 groups

  1. Obese group with a BMI ≥ 30 with type 2 diabetes,
  2. Obese group with a BMI ≥ 30 without any type of diabetes,
  3. Control group of participants with a BMI between 18.5 and 24.9 kg/m2 and without any type of diabetes.

will be recruited. Blood, urine, and stool samples will be collected from participants. A questionnaire to collect sociodemographic characteristics as well as behaviors and lifestyle habits related to diet, physical activity, and psychological health.

02

Conditions studied

  • Diabetes Mellitus, Type 2
  • Obesity

Keywords

  • microbiota
  • New Caledonia
  • metabolic diseases
03

In context

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's planned enrollment of 270 is close to the median of 300 across 1,748 observational studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Institut Pasteur is the lead sponsor of 99 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Adults living in New Caledonia who are obese with or without type 2 diabetes or healthy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 60 years.
  • Ability to understand and provide .
  • Ability and willingness to meet the required schedule and study interventions.
  • Willingness to share their community belonging
  • Benefit from a social security system.

For obese and diabetic patients :

  • IMC ≥ 30 kg/m² with type 2 diabetes
  • Fasting plasma glucose (FPG) ≥7 mM (=1.26g/l) or
  • Patients with ≥ 6.5% (48 mmol/mol)
  • All stages of albuminuria For obese patients without type 2 diabetes
  • IMC ≥ 30 kg/m²
  • Weight stable for at least 2 months
  • Patients with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) and an HbA1c \< 6.5 %
  • No treatment (diabetic or weight loss)
  • Match age (±5years), sex and self-reported community to the patients from the1 group.

For control group :

  • between 18.5-24.9 kg/m²
  • Match age (±5years), sex and self-reported community to the patients from the 1 and 2 groups.
  • Participants with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) and an HbA1c \< 6.5 %

Exclusion criteria

Exclusion Criteria:

All participants :

  • Treatment that may alter gastrointestinal motor function, acidity, microbial population, or
  • Altered anatomy of the esophagus, stomach, small intestine, or large intestine due to gastrointestinal surgery (except appendectomy or cholecystectomy)
  • Chronic or acute inflammatory bowel disease or infections
  • Abdominal or pelvic radiation therapy or abdominal cancer, colorectal cancer
  • Dysphagia, eosinophilic esophagitis, esophageal stricture, or other swallowing disorders
  • Organ transplantation and patients receiving immunosuppressive therapy
  • Severe renal failure and/or patients undergoing dialysis
  • Cardiovascular, endocrine, renal, or other chronic disease that may affect motility.
  • Preparation for colon cleansing within the last month
  • \< 3 bowel movements per week
  • Women who are pregnant or breastfeeding
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
270 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Obese group with a BMI ≥30 with type 2 diabetes

    Other: 25 ml blood sample · Other: Urine sample · Other: Stools

  • Obese group with a BMI ≥30 without any type of diabetes

    Other: 25 ml blood sample · Other: Urine sample · Other: Stools

  • Control group of participants considered as "metabolically healthy"

    Other: Urine sample · Other: Stools · Other: 40 ml blood sample

Interventions

  • Other25 ml blood sample

    A 25-ml blood sample

  • OtherUrine sample

    A 10-ml urine sample

  • OtherStools

    10-g stools

  • Other40 ml blood sample

    A 40-ml blood sample

06

What researchers measure

Primary outcomes

  1. Describe and characterise the faecal microbiota of patients to investigate the relationships between microbiota composition with bioclinical parameters

    Microbiota will be analysed through 16S rRNA gene sequencing as well as shotgun metagenomic sequencing of the different samples obtained from the faecal sample

    Time frame: 6 years

  2. Describe and characterise the faecal microbiota and metabolome of patients to investigate the relationships between microbiota composition with bioclinical parameters

    microbiome and metabolites from collected human fecal samples will be analyzed using a standardized extraction protocol designed for Liquid chromatography-mass spectrometry (LC/MS)-based metabolomics to detect short-chain fatty acids and bile acids,…. which are mainly produced by bacteriasequencing of the different samples obtained from the faecal sample.

    Time frame: 6 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Feb 2027, 12 months later.

Of 170 industry-sponsored observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 44. This study's planned 12 months is below that.

Counting every sponsor, half of 604 studies reached it within 32 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Oct 3, 2025
StartEst.
Feb 15, 2026
Primary completionEst.
Feb 15, 2027
CompletionEst.
Feb 15, 2027
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07205913
Lead sponsor
Institut Pasteur
Collaborators
RIKEN Center for Integrative Medical Sciences
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Feb 15, 2026 (estimated)
Primary completion
Feb 15, 2027 (estimated)
Completion
Feb 15, 2027 (estimated)
Last update
Mar 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion